AQP4
Aquaporin-4
Also known as: AQP-4, AQP4_HUMAN, hAQP4, MIWC
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P55087
- Gene
- AQP4
- Ensembl
- ENSG00000171885
- Chromosome
- 18
- Canonical length
- 323 aa
- Protein class
- Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters
- Subcellular location
- Plasma membrane,Cell Junctions
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes a member of the aquaporin family of intrinsic membrane proteins that function as water-selective channels in the plasma membranes of many cells. This protein is the predominant aquaporin found in brain and has an important role in brain water homeostasis. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. Additional isoforms, resulting from the use of alternative in-frame translation initiation codons, have also been described. Recent studies provided evidence for translational readthrough in this gene, and expression of C-terminally extended isoforms via the use of an alternative in-frame translation termination codon. [provided by RefSeq, Jun 2018]
Canonical amino-acid sequenceUniProt
323 residues, UniProt reviewed canonical sequence.
>P55087|AQP4
1 MSDRPTARRW GKCGPLCTRE NIMVAFKGVW TQAFWKAVTA EFLAMLIFVL LSLGSTINWG
61 GTEKPLPVDM VLISLCFGLS IATMVQCFGH ISGGHINPAV TVAMVCTRKI SIAKSVFYIA
121 AQCLGAIIGA GILYLVTPPS VVGGLGVTMV HGNLTAGHGL LVELIITFQL VFTIFASCDS
181 KRTDVTGSIA LAIGFSVAIG HLFAINYTGA SMNPARSFGP AVIMGNWENH WIYWVGPIIG
241 AVLAGGLYEY VFCPDVEFKR RFKEAFSKAA QQTKGSYMEV EDNRSQVETD DLILKPGVVH
301 VIDVDRGEEK KGKDQSGEVL SSVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AQP4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 6
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 354 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 354 nTPM
- amygdala: 251 nTPM
- basal ganglia: 242 nTPM
- midbrain: 174 nTPM
- hippocampal formation: 129 nTPM
- lung: 108 nTPM
Single-cell type
- astrocytes: 743 nCPM
- alveolar cells type 1: 568 nCPM
- transitional alveolar cells: 392 nCPM
- alveolar cells type 2: 318 nCPM
- ependymal cells: 261 nCPM
- müller glia: 227 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 925 nTPM
- thalamus: 815 nTPM
- white matter: 755 nTPM
- midbrain: 727 nTPM
- medulla oblongata: 693 nTPM
- spinal cord: 682 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AQP4.
Disease | AllUniProt
Conditions AQP4 is implicated in, by any mechanism.
- Megalencephalic leukoencephalopathy with subcortical cysts 4, remitting (MLC4) MIM:620448
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 54 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Intellectual disability
- Megalencephalic leukoencephalopathy with subcortical cysts 4, remitting
Disease | ImmuneIEDB
Conditions an epitope on AQP4 was assayed in.
- neuromyelitis optica B and T cell
- multiple sclerosis B and T cell
- autoimmune disease of central nervous system T cell
- Sjogren's syndrome B cell
- systemic lupus erythematosus B cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against AQP4 are reported. Each links to that disease's full target list.
- Neuromyelitis Optica 1,174
- Multiple Sclerosis 220
- Sjogren's Syndrome 32
- Neoplasm Recurrence, Local 27
- Lupus Erythematosus, Systemic 26
- COVID-19 21
- Myasthenia Gravis 21
- Encephalitis 17
- Autoimmune Diseases of the Nervous System 14
- Encephalomyelitis, Autoimmune, Experimental 11
- Paraneoplastic Syndromes, Nervous System 7
- Seizures 7
- Lung Neoplasms 6
- Pain 6
- Adenocarcinoma 5
- Brain Diseases 5
- Breast Neoplasms 5
- Muscle Weakness 5
- Guillain-Barre Syndrome 4
- Hashimoto Disease 4
Showing 20 of 59 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for AQP4 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1,550 publications
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
2024 · J Neurol · RCR 47.1 · 197 citations - The spectrum of neuromyelitis optica.
2007 · Lancet Neurol · RCR 45.3 · 1,693 citations - Myelin-oligodendrocyte glycoprotein antibody-associated disease.
2021 · Lancet Neurol · RCR 32.1 · 424 citations - Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
2019 · N Engl J Med · RCR 31.4 · 652 citations - Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
2014 · Neurology · RCR 25.2 · 671 citations
Show 20 more of 1,550 total
- Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
2018 · Neurology · RCR 24.4 · 455 citations - Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
2023 · J Neurol · RCR 24.2 · 158 citations - Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
2019 · Nat Rev Neurol · RCR 24.2 · 467 citations - Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
2019 · N Engl J Med · RCR 23.6 · 496 citations - Neuromyelitis optica.
2020 · Nat Rev Dis Primers · RCR 22.4 · 386 citations - Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.
2017 · Ann Neurol · RCR 19.7 · 441 citations - Aquaporin water channels in the nervous system.
2013 · Nat Rev Neurosci · RCR 19.7 · 583 citations - Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
2014 · JAMA Neurol · RCR 17.9 · 481 citations - Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
2019 · JAMA Neurol · RCR 17.3 · 284 citations - The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.
2020 · Acta Neuropathol · RCR 17.1 · 299 citations - Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
2023 · Neurology · RCR 16.6 · 103 citations - Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children.
2020 · JAMA Neurol · RCR 16.5 · 287 citations - Autoantibodies in neurological disease.
2021 · Nat Rev Immunol · RCR 16.1 · 249 citations - MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
2016 · J Neuroinflammation · RCR 15.6 · 353 citations - NMOSD and MOGAD: an evolving disease spectrum.
2024 · Nat Rev Neurol · RCR 15.5 · 85 citations - Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.
2018 · JAMA Neurol · RCR 15.5 · 322 citations - Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.
2014 · Ann Neurol · RCR 15 · 388 citations - Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
2012 · Neurology · RCR 14.3 · 427 citations - International multicenter examination of MOG antibody assays.
2020 · Neurol Neuroimmunol Neuroinflamm · RCR 14.2 · 223 citations - Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
2024 · Ann Neurol · RCR 14.1 · 55 citations
Reference: B cellIEDB
3 publications
- High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.
2016 · Mol Cell Proteomics · RCR 2.5 · 66 citations - Fine specificity of antibodies against AQP4: epitope mapping reveals intracellular epitopes.
2011 · J Autoimmun · RCR 0.9 · 29 citations - Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis.
2013 · J Neuroimmunol · RCR 0.2 · 7 citations
Reference: T cellIEDB
4 publications
- Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.
2012 · Ann Neurol · RCR 7.8 · 279 citations - Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
2020 · Front Immunol · RCR 1.5 · 29 citations - Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica.
2011 · Int Immunol · RCR 1.3 · 52 citations - T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO).
2016 · Mult Scler Relat Disord · RCR 1 · 28 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.99
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.19
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to type II interferon
- cerebrospinal fluid circulation
- intracellular water homeostasis
- multicellular organismal-level water homeostasis
- protein homotetramerization
- renal water homeostasis
- water transport
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AQP4 as an antibody target. Whether an autoantibody or antibody against AQP4 could matter depends on whether native AQP4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AQP4 is annotated at the cell surface, where native AQP4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label AQP4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...